Aurinia Pharmaceuticals Inc logo
AUPH

Aurinia Pharmaceuticals Inc

MaveScore 36 Low model confidence
Last Price US$15.78 As of Jul 10, 2026
DCF Fair Price US$17.28 Research estimate · Jul 10, 2026 +4.1% vs price
Market Cap US$2.1b Company size context
7D Performance 1.09% Past 7 days
1Y Performance 76.71% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Mar 31, 2026

103 days old

Market price date

Jul 10, 2026

2 days old

Coverage

16/16

No missing model inputs

Data quality

Excellent

Current stored snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 36 Low confidence

Stored data quality

Freshness and coverage checks

16/16 Current stored snapshot

Quality

13/35 Weak

Blends latest model rank with profitability and dilution ranks.

Financial Strength

14/25 Mixed

Rewards durable profitability, margins, and positive free cash flow.

Valuation Support

3/15 Weak

Favors positive earnings, positive cash flow, and lower multiples.

Momentum

5/15 Weak

Highlights research candidates with supportive 3-month and 6-month price regimes.

Shareholder Alignment

1/10 Weak

Rewards less dilutive share behavior and enough size for liquid research coverage.

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Blends latest model rank with profitability and dilution ranks.
  • Favors positive earnings, positive cash flow, and lower multiples.
  • Highlights research candidates with supportive 3-month and 6-month price regimes.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

Dashboard Funda..tals Prediction Screener Map

Aurinia Pharmaceuticals Inc Overview

Industry: Biotechnology

Sector: Healthcare

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It Read More

Aurinia Pharmaceuticals Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

Aurinia Pharmaceuticals Inc

Score

Reported Results

What the company reported, with filing details kept small.

Filed May 07, 2026

Quarterly result summary

Revenue was $77.7M (+24% YoY); EPS was $0.25 (+56% YoY).

Revenue $77.7M +24% YoY
EPS $0.25 +56% YoY
Operating income $41.4M +90% YoY
Net income $34.4M +48% YoY

What changed

  • Revenue +24% YoY to $77.7M; EPS +56% YoY to $0.25.
  • Operating income +90% YoY to $41.4M.
  • Net income +48% YoY to $34.4M.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

Earnings release Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials

Recent News



Earnings Per Share

Score 4.00/5
Aurinia Pharmaceuticals Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Return on Equity

Score 1.77/5
Aurinia Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Aurinia Phar... AUPH US$2.1b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Net Margin

Score 1.41/5
Aurinia Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Aurinia Phar... AUPH US$2.1b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Share Buyback

In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Leverage

Score 3.68/5
Aurinia Pharmaceuticals Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Aurinia Phar... AUPH US$2.1b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

SEC financial statements are temporarily unavailable.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Aurinia Pharmaceuticals Inc logo

Aurinia Pharmaceuticals Inc

US$15.78

US$17.28

+4.1% vs price

US$2.1b

1.09%

76.71%